| 58.005 0 (0%) | 03-06 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 67.75 | 1-year : | 79.13 |
| Resists | First : | 58 | Second : | 67.75 |
| Pivot price | 57.91 |
|||
| Supports | First : | 57.76 |
Second : | 57.61 |
| MAs | MA(5) : | 58 |
MA(20) : | 57.87 |
| MA(100) : | 40.23 |
MA(250) : | 22.9 |
|
| MACD | MACD : | 1.9  |
Signal : | 2.5 |
| %K %D | K(14,3) : | 98.3 |
D(3) : | 98.3 |
| RSI | RSI(14): 79 | |||
| 52-week | High : | 58 | Low : | 5.66 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RAPT ] has closed below upper band by 27.6%. Bollinger Bands are 96.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 58.06 - 58.34 | 58.34 - 58.58 |
| Low: | 57.32 - 57.65 | 57.65 - 57.94 |
| Close: | 57.51 - 58.02 | 58.02 - 58.46 |
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical firm specializing in immunology. The company is dedicated to discovering, developing, and commercializing innovative oral small molecule therapies. These treatments are aimed at addressing critical unmet medical needs for patients battling oncology and inflammatory diseases. Its primary drug candidate for inflammation, RPT193, functions as a C-C motif chemokine receptor 4 (CCR4) antagonist. This compound works by selectively preventing type 2 T helper cells from migrating into inflamed tissues. In the oncology pipeline, FLX475 stands as the company's leading candidate, also an oral small molecule CCR4 antagonist. This therapy is currently undergoing Phase 1/2 clinical trials to evaluate its efficacy both as a standalone treatment and in combination with pembrolizumab for individuals with advanced cancer. RAPT Therapeutics is also engaged in the development of a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Founded in 2015, the company initially operated as FLX Bio, Inc. before rebranding as RAPT Therapeutics, Inc. in May 2019. Its corporate headquarters are situated in South San Francisco, California.
Thu, 11 Jun 2026
TD Cowen initiates coverage of RAPT Therapeutics (RAPT) with buy recommendation - MSN
Tue, 03 Mar 2026
RAPT Therapeutics (NASDAQ: RAPT) to Be Acquired at $58 Per Share - Stock Titan
Wed, 21 Jan 2026
GSK acquires food allergy firm Rapt Therapeutics for $2.2bn - European Pharmaceutical Review
Tue, 20 Jan 2026
GSK to Acquire Rapt for $2.2B, Adding Food Allergy Candidate to Pipeline - Genetic Engineering and Biotechnology News
Tue, 20 Jan 2026
GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal - statnews.com
Tue, 20 Jan 2026
Latham & Watkins Advises on GSK’s US$2.2 Billion Acquisition of RAPT Therapeutics - Latham & Watkins LLP
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 110.5 (%) |
| Shares Short | 2,240 (K) |
| Shares Short P.Month | 1,780 (K) |
| EPS | -11.66 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.4 % |
| Return on Equity (ttm) | -85.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -87 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -4.98 |
| PEG Ratio | 0 |
| Price to Book value | 6.43 |
| Price to Sales | 0 |
| Price to Cash Flow | -19.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|